ARMP SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 25, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War for AP-SA02 Phase 3 Development

Sep 23, 2026

8-K

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

Sep 14, 2026

8-K

Armata Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 12, 2026

8-K

Armata Pharmaceuticals Advances AP-SA02 Toward Phase 3 Clinical Trial

Jul 20, 2026

8-K

Armata Pharmaceuticals Appoints David House as Chief Financial Officer

Jul 20, 2026

8-K

Armata Pharmaceuticals Reaches Agreement with FDA on Pediatric Study Plan for AP-SA02

Jul 13, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

December 2025 ATM | Offering amount: $100,000,000

Dec 1, 2025

424B3

UPDATED

Apr 6, 2023

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 13,500,000 | Warrants amount: 4,500,000

May 31, 2022

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 2,121,213

Apr 6, 2022

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 12,307,694 | Warrants amount: 6,153,847

May 20, 2021

424B3

$100,000,000

Apr 9, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 10, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 13, 2025

S-3

August 2025 SHELF | Offering amount: $100,000,000 | Float: 11,077,705

Aug 13, 2025

S-8

Registration

Jan 23, 2024

S-8

Registration

Nov 15, 2023

S-3/A

SHARE RESALE REGISTRATION | Shares amount: 21,315,790 | Share price: $1.46 EFFECTIVE

Mar 28, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 27, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2024

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Aug 3, 2023

DEF 14A

Form DEF 14A - Other definitive proxy statements

Aug 3, 2023

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Jul 24, 2023

Ownerships

TYPE

HEADLINE

FILED AT

Birx Deborah (Reporting)

Jul 14, 2026

SCHEDULE 13D/A

Innoviva, Inc. (Filed by)

May 13, 2026

Gilmer Daniel B. (Reporting)

Apr 28, 2026

Gilmer Daniel B. (Reporting)

Apr 28, 2026

Kyme Pierre (Reporting)

Mar 17, 2026

Birx Deborah (Reporting)

Mar 17, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 25, 2025

CORRESP

Form CORRESP - Correspondence

Aug 20, 2025

LETTER

Form UPLOAD - SEC-generated letter

Aug 15, 2025

LETTER

Form UPLOAD - SEC-generated letter

Nov 13, 2023

CORRESP

Form CORRESP - Correspondence

Nov 7, 2023

LETTER

Form UPLOAD - SEC-generated letter

Oct 26, 2023

Armata Pharmaceuticals, Inc. ARMP · SEC Filings